In 2022, the FDA approved DS-8201 for unresectable or metastatic HER2+ breast cancer adult patients who had received a prior anti-HER2-based regimen in the metastatic setting or the neoadjuvant or adjuvant setting however, had developed disease recurrence during or within 6 months of completing therapy. The gene discussed is ERBB2; the disease is breast cancer.